Aug 2026· İstanbul Kuzey Klinikleri· Vol 13, pp. 403 - 412· 0 citations· 30 references
Medicine
TL;DR
This study delineates the genomic landscape of C. auris Clade I, highlighting how the consolidation of multiple resistance and virulence markers contributes to its clinical success.
Abstract
Objective
Candidozyma auris has emerged as a global “urgent threat” characterized by multidrug resistance and high mortality. While six distinct lineages have been identified, Clade I (South Asian) is the primary driver of global nosocomial outbreaks and exhibits the most profound resistance profiles. This study aims to provide a high-resolution genomic characterization of Clade I, focusing on the consolidation of resistance mechanisms and virulence factors that support its global dominance.
Methods
We performed a comprehensive genomic analysis focusing on a cohort of 647 Clade I isolates, selected from a total of 662 global C. auris genomes available in public repositories. Using a standardized bioinformatic pipeline, we conducted core-genome single-nucleotide polymorphisms-based phylogenetic reconstruction, non-synonymous mutation profiling of key resistance genes (TAC1B, FKS1, ERG11/6/3), and functional mapping of virulence-related pathways (ALS4, secretable aspartyl proteases [SAP5], LIP1). The remaining isolates from Clades II to VI were utilized as comparative reference groups to identify clade-specific signatures.
Results
Analysis of the Clade I cohort (n=647; 97.73% of the total dataset) revealed a significant consolidation of resistance markers. The Y132F and K143R substitutions in ERG11 were near-ubiquitous, often co-occurring with specific TAC1B variants (A640V, V742A). Notably, 24.32% of the Clade I isolates demonstrated a highly synchronized “genomic armor,” characterized by the simultaneous presence of TAC1B (A:YTDQ/A:GSVG), FKS1 (S:SL), and deletions in ERG6/ERG3. Virulence profiling showed high-frequency conservation of biofilm-associated (ALS4) and proteolytic (SAP5) genes, suggesting a synergistic evolution of resilience and pathogenicity.
Conclusion
This study delineates the genomic landscape of C. auris Clade I, highlighting how the consolidation of multiple resistance and virulence markers contributes to its clinical success. The high frequency of multidrug-resistant genotypes within this lineage mandates a transition toward genome-led surveillance and personalized antifungal stewardship.
ABSTRACT Candida (Candidozyma) auris (C. auris) poses an urgent public health threat due to its widespread emergence, antimicrobial resistance, and ability to cause severe infections and outbreaks associated with high mortality rates. In this study, we phenotypically and genotypically characterized antifungal susceptib...
S. Satia, Jennifer Pfeiffer, Abdullah Kilic et al.· Microbiology spectrum· 0 citations
C. auris is an emerging multidrug-resistant (MDR) fungal pathogen that poses an urgent threat to global public health. It is characterized by rapid nosocomial transmission, persistent environmental survival, and extensive cross-resistance to conventional antifungal therapies. This comprehensive narrative review bridges...
The taxonomic distribution, antimicrobial resistance genes (ARGs), virulence-associated genes (VAGs), sequence types (STs), predicted mobile genetic elements (MGEs), orthogroup-occupancy patterns, and core-genome sequence variation of publicly available S. maltophilia isolates were characterized using complementary bio...
Rong-Zheng Sun, Yan-Dan Liu, Xiao-Li Cao et al.· Frontiers in Microbiology· 0 citations
Introduction Candidozyma auris is an emerging healthcare-associated fungal pathogen with a high propensity for nosocomial transmission and development of antifungal resistance. This study aimed to identify resistance-associated genomic variants and characterize the phylogenetic structure of clinical C. auris isolates c...
E. Oganesyan, A. Zhuk, K. V. Gusarova et al.· Frontiers in Cellular and In...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.